Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer StudyBusiness Wire · 1 day ago
First and Only Ulcerative Colitis Treat-to-Target Trial Shows Treating to Disease Clearance vs. Symptomatic Remission with ENTYVIO® (vedolizumab) Prolongs Time to First Disease-Related ComplicationBusiness Wire · 6 days ago
Takeda's ORZEYFUL (oveporexton) Launches Simultaneously in Japan and China Giving Physicians First Access to Prescribe Novel Orexin Agonist to Patients with Narcolepsy Type 1Business Wire · Oct 14, 2026
Takeda Presents Phase 2/3 IgGNITE Study Results of Investigational Subcutaneous TAK-881 in Primary Immunodeficiency Disease (PID) at ESID 2026Business Wire · Oct 14, 2026
Takeda Remains A Buy, Boosted By Recent Narcolepsy Drug Approval And Robust PipelineSeeking Alpha · Oct 13, 2026
Critical Contrast: ProPhase Labs (NASDAQ:PRPH) & Takeda Pharmaceutical (NYSE:TAK)Defense World · Oct 1, 2026Takeda Pharmaceutical Company Limited is a prominent global biopharmaceutical entity dedicated to the discovery, development, manufacturing, commercialization, and out-licensing of pharmaceutical products. The company's operations extend across a vast international footprint, encompassing Japan, the United States, Europe, Canada, Latin America, Russia, and numerous other Asian and worldwide markets. Its extensive portfolio of medicines targets critical therapeutic areas, including digestive disorders (gastroenterology), rare diseases, plasma-derived treatments, cancer care (oncology), and neurological conditions.
| Date | Est. | Actual | |
|---|---|---|---|
| Jul 30, 2026 | $0.17 | $0.23 | Beat |
| May 13, 2026 | $0.21 | -$0.05 | Miss |
| Jan 29, 2026 | $0.55 | $0.21 | Miss |
| Oct 30, 2025 | $0.44 | -$0.02 | Miss |
| Jul 30, 2025 | $0.47 | $0.52 | Beat |
| May 8, 2025 | $0.24 | -$0.22 | Miss |